Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › trilaciclib

trilaciclib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of trilaciclib

4 trials tracked of trilaciclib.

4Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 4
  1. Phase 2 Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Completed
  2. Phase 2 Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Completed
  3. Phase 2 Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer Completed
  4. Phase 2 Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis evaluates trilaciclib for chemotherapy-induced myelosuppression in solid tumors
Drug Pipeline Meta-analysis
Systematic review and meta-analysis evaluates trilaciclib for chemotherapy-induced myelosuppression in solid tumors Could a new drug help cancer patients keep their blood counts up and feel better during tough chemo?
This systematic review and meta-analysis evaluated trilaciclib in 726 patients with solid tumors receiving chemotherapy.
A new drug called trilaciclib helps cancer patients avoid dangerous drops in white blood cells and feel better during tough chemotherapy tre…
Frontiers Apr 18, 2026